INVA Innoviva, Inc. stock chart & analysis
Conviction 58HealthcareScan · Fri, Nov 6, 2026Innoviva, Inc. (INVA) closed at $19.10 (-0.73%) on Nov 6, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 31, RS Rating 53, -24.0% from its 52-week high, -4.4% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Wed, Sep 30, 2026 · quarterly.
INVA technical analysis
Trend
INVA is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 8.6% below the 50-day ($20.91) and 12.8% below the 200-day ($21.90). ADX(14) at 16 points to a weak trend — more range than direction. It meets 2 of 8 trend-template criteria.
Momentum
RSI(14) is 31, in the bearish half of its range. MACD crossed below its signal line one session ago. A bearish MACD divergence is in place. Its RS Rating of 53 puts its weighted 12-month performance ahead of about 53% of the US market.
Volume and volatility
Volume on the latest session ran 2.2× its 20-day average. It trades about $16.7M a day on average. ATR(14) is $0.6221, 3.3% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (-0.38) shows distribution.
Key levels
The chart pattern's support is $20.34 and its resistance $21.71. The 52-week range is $18.85 to $25.15; price is 24.0% below the high and 1.4% above the low. The VWAP anchored at the 52-week high is $21.86, above price.
Performance
INVA returned -10.0% (1 week), -8.5% (1 month), -7.6% (3 months), -16.5% (6 months), +4.8% (1 year), -4.4% (year to date).
About Innoviva, Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
Pharmaceutical Preparations · Listed 2004 · 159 employees
Recent news
- Innoviva, Inc.: Earnings resultsSEC EDGAR · Wed, Nov 4, 2026
Congress activity
Disclosed STOCK Act trades in INVA · 2 recent
Insider activity
SEC Form 4 transactions in INVA
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Basso Stephen Chief Financial Officer · Common Stock · 2026-08-20 | Tax | 558 | $12K | 2026-08-20 | 2026-08-24 |
Raifeld Pavel Chief Executive Officer · Common Stock · 2026-08-20 | Tax | 1.13K | $24K | 2026-08-20 | 2026-08-24 |
Zhen Marianne Chief Accounting Officer · Common Stock · 2026-08-20 | Tax | 1.13K | $24K | 2026-08-20 | 2026-08-24 |
Raifeld Pavel Chief Executive Officer · Common Stock · 2026-05-20 | Tax | 1.13K | $25K | 2026-05-20 | 2026-05-22 |
Basso Stephen Chief Financial Officer · Common Stock · 2026-05-20 | Tax | 559 | $12K | 2026-05-20 | 2026-05-22 |
Zhen Marianne Chief Accounting Officer · Common Stock · 2026-05-20 | Tax | 1.13K | $25K | 2026-05-20 | 2026-05-22 |
Raifeld Pavel Chief Executive Officer · Common Stock · 2026-05-15 | Grant | 1.12K | $0 | 2026-05-15 | 2026-05-22 |
Basso Stephen Chief Financial Officer · Common Stock · 2026-05-15 | Grant | 1.12K | $0 | 2026-05-15 | 2026-05-22 |
Linden Josephine Director · Non-statutory Stock Option · 2026-05-18 | Grant | 9.17K | $0 | 2026-05-18 | 2026-05-20 |
Linden Josephine Director · Common Stock · 2026-05-18 | Grant | 5.73K | $0 | 2026-05-18 | 2026-05-20 |
SEC filings
EDGAR filings in INVA · 6 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.